Given the pandemic situation and an increasing burden of chronic diseases, it is more important now to adopt remote patient monitoring to offer better access to healthcare and avoid advanced stages of the disease by addressing the changing health status of patients quickly.
Biotricity — a medical technology company focused on delivering remote biometric monitoring solutions — has introduced Biokit: a personal medical device kit for remote monitoring of patients with cardiac diseases.
Remote patient monitoring (RPM) is a method that uses technology to monitor and gather biometric data, such as blood pressure and ECG, and transmit it electronically to the physician for timely assessment, recommendations, and instructions. All of this happens remotely, outside of traditional healthcare settings.
Biokit has been developed to solve the issues patients and physicians face with existing solutions for remote monitoring of cardiac disease. It includes three devices: Biokit BP, Biokit TP, and Biokit 02.
- Biokit BP is used to measure blood pressure through a wireless digital blood pressure cuff.
- Biokit TP is a digital thermometer.
- Biokit 02 is a digital pulse oximeter that measures the oxygen saturation of the patient.
What is unique about this kit is that all three devices are integrated with the Biotricity Ecosystem that allows doctors and patients to access and track the real-time medical data on the website as well as the app. This integration is of great help during interim reviews and follow-up visits.
Boikit is the extension of Bioflux, a small, cardiac telemetry device by Biotricity developed for the monitoring of ECG information in patients diagnosed with cardiac disease. All three devices of Biokit have been cleared by the FDA, and the kit is expected to be available for customers by early 2022.
Using Biokit along with Bioflux for remote patient monitoring will definitely help physicians to support, educate, and provide timely feedback to their patients, hence reducing the number of hospitalizations and readmissions. It will also translate to a reduced annual cost of managing cardiac conditions.
